Revvity stock holds in the low-$120s as valuation stretches above analyst targets

Revvity Inc. (US76155R1086) stock is quoted at $123.25 on the New York Stock Exchange as of August 21, 2026, with the shares up 27.3% from a 52-week low of $96.80 earlier in the year, according to the latest stock overview. The same overview indicates that the current quote of $123.25 reflects a modest intraday decline of 0.71% on August 21, 2026, from a prior close of $124.13, underscoring how the shares are consolidating gains ahead of upcoming catalysts.

Share price stretches above consensus targets

Recent market data compiled in the latest stock overview highlights that Revvity stock is trading at $123.25 in intraday action on August 21, 2026, while the average analyst price target stands at $108.36, implying the shares trade 13.7% above the current analytical expectation and signaling a valuation premium relative to consensus. A detailed NYSE overview shows that the consensus price target of $108.36 represents downside of 12.1% from the $123.25 trading level, reflecting a cautious stance from the analyst community despite the stock's year-to-date performance. The same overview notes that Revvity stock was trading at $96.81 on January 1, 2026 and has since increased to $123.25, a gain of 27.3% that places the current price well above the earlier low in the $90s area.

Institutional ownership updates reported in the latest coverage point to continued interest from large investors, with one recent filing citing a purchase of 43,063 shares and another noting a larger position of 148,853 shares, both aligned with a consensus rating that classifies Revvity shares as a hold and anchors the average price target at $108.36. An institutional positioning alert emphasizes that these stake increases contribute to a $45.44 million position in Revvity shares, suggesting that professional investors are willing to maintain exposure even as the market price trades above consensus estimates. For valuation-focused investors, the gap between the $123.25 trading level and the $108.36 target has become a central consideration as they weigh the risk of a pullback against the company’s earnings outlook.

Fundamental backdrop and earnings momentum

While the freshest detailed quarterly figures for Revvity are not fully restated in the day-filtered market snapshots, the earnings history referenced in the NYSE overview provides context for how the company has executed against expectations in the past. The earnings section notes that in a recent quarterly report Revvity delivered earnings per share of $1.41, exceeding a consensus estimate of $1.21 by $0.20, and that revenue in the same quarter declined 1.3% year-over-year, illustrating a pattern of margin resilience even when topline growth is modest. Because this specific report is dated well before June 30, 2025 in the referenced transcript and therefore falls outside the strict nine-month freshness window relative to August 22, 2026, these figures serve as historical context rather than current metrics, but they nonetheless show the company’s capacity to outperform earnings expectations while managing a slight revenue contraction.

In the current market environment, investors looking at Revvity’s diagnostics and research profile are watching for the next set of interim results to gauge whether revenue growth has re-accelerated and whether the company can sustain or extend prior margin achievements. The analyst consensus embedded in the $108.36 price target implicitly reflects forecasts that balance revenue and earnings trends with broader sector dynamics in life sciences tools and diagnostics, an area where demand often ties to capital spending cycles in pharma and biotech. With the shares already trading 13.7% above this consensus level based on the latest $123.25 quote, any upcoming earnings release that shows stronger-than-expected revenue growth or improved operating leverage could justify the premium, while a miss on either dimension would heighten the risk that the stock gravitates back towards the target range.

For investors, the key quantified takeaway today is that Revvity shares are positioned between their 52-week low and the consensus price target in a way that reveals a clear asymmetry: the 27.3% rebound from the $96.80 low has already materialized, yet the current price still exceeds analyst expectations by double digits. That tension often makes valuation discipline more important, as the market has effectively discounted a degree of future earnings strength into the low-$120s trading band ahead of any new quarterly data, leaving less margin for disappointment when the next results arrive.

Diagnostics and life sciences offerings

Beyond the numbers, Revvity’s business is rooted in providing advanced diagnostics, life sciences tools, and scientific instrumentation that support research and clinical workflows across multiple end markets, including reproductive health, infectious disease testing, and laboratory automation. The company’s portfolio includes instruments, reagents, and software platforms that help laboratories generate high-quality data for genomic analysis, screening, and imaging, enabling customers to accelerate discovery and improve diagnostics accuracy. By combining hardware with consumables and informatics, Revvity aims to create recurring revenue streams and deepen customer relationships in academic, biopharmaceutical, and clinical settings, a model that can enhance earnings visibility when adoption is strong.

A representative part of Revvity’s offering is its suite of prenatal screening solutions, which integrate assay technologies with data interpretation tools to deliver risk assessments for chromosomal abnormalities in unborn children. These products rely on robust analytical sensitivity and specificity, and their performance metrics are routinely validated against clinical outcomes, creating a feedback loop that helps refine test algorithms and maintain regulatory compliance. In parallel, the company’s imaging systems allow researchers to visualize biological processes in real time, powering high-content screening applications where throughput and image quality both matter for the reliability of conclusions drawn from experiments.

Revvity stock price context

Revvity stock, listed under the ticker RVTY on the New York Stock Exchange, continues to trade in the low-$120s as of August 21, 2026, with the latest quoted price of $123.25 USD standing above the $108.36 consensus target and well above the 52-week low of $96.80, highlighting a share price that has already priced in optimism regarding future earnings progress and market share gains in diagnostics and research tools.

Fact box

Company: Revvity Inc.

ISIN: US76155R1086

Ticker: RVTY

Exchange: New York Stock Exchange

Price (as of August 21, 2026, 11:05 a.m. ET): $123.25 USD

Market cap: $12.79 billion (as of August 22, 2026)

Sector / Industry: Health care - Diagnostics and research

Index membership: S&P 500